BioVision |
2044-25 |
CHS-828
|
25 mg |
|
|
BioVision |
2045-1 |
YM201636
|
1 mg |
|
|
BioVision |
2044-5 |
CHS-828
|
5 mg |
|
|
BioVision |
2042-250 |
RO 20-1724
|
250 mg |
|
|
BioVision |
2043-1 |
Skyrin, Talaromyces sp.
|
1 mg |
|
|
BioVision |
2042-50 |
RO 20-1724
|
50 mg |
|
|
BioVision |
2041-50 |
WY-14643
|
50 mg |
|
|
BioVision |
2041-10 |
WY-14643
|
10 mg |
|
|
BioVision |
2039-1 |
RO-3306
|
1 mg |
|
|
BioVision |
2039-5 |
RO-3306
|
5 mg |
|
|
BioVision |
2040-5 |
BCl-2 Inhibitor GX15-070
|
5 mg |
|
|
BioVision |
2038-100 |
Ilimaquinone
|
100 μg |
|
|
BioVision |
2037-5 |
Spautin-1
|
5 mg |
|
|
BioVision |
2037-25 |
Spautin-1
|
25 mg |
|
|
BioVision |
2036-5 |
Dodecyl-β-D-maltopyranoside
|
5 g |
|
|
BioVision |
2036-25 |
Dodecyl-β-D-maltopyranoside
|
25 g |
|
|
BioVision |
2036-50 |
Dodecyl-β-D-maltopyranoside
|
50 g |
|
|
BioVision |
2035-25 |
Fatostatin
|
25 mg |
|
|
BioVision |
2036-1 |
Dodecyl-β-D-maltopyranoside
|
1 g |
|
|
BioVision |
2034-10 |
Bikinin
|
10 mg |
|
|
BioVision |
2034-50 |
Bikinin
|
50 mg |
|
|
BioVision |
2035-5 |
Fatostatin
|
5 mg |
|
|
BioVision |
2032-5 |
Aclacinomycin A
|
5 mg |
|
|
BioVision |
2032-25 |
Aclacinomycin A
|
25 mg |
|
|
BioVision |
2033-10 |
MDBN
|
10 mg |
|
|
BioVision |
2033-50 |
MDBN
|
50 mg |
|
|
BioVision |
2031-25 |
EZSolution™ BAY 43-9006
|
25 mg |
|
|
BioVision |
2028-10 |
Bilobalide
|
10 mg |
|
|
BioVision |
2028-50 |
Bilobalide
|
50 mg |
|
|
BioVision |
2029-25 |
EZSolution™ Dasatinib
|
25 mg |
|
|
BioVision |
2030-5 |
EZSolution™ Gefitinib
|
5 mg |
|
|
BioVision |
2027-1 |
BAY 58-2667 Hydrochloride
|
1 mg |
|
|
BioVision |
2026-25 |
Vatalanib, Free Base
|
25 mg |
|
|
BioVision |
2025-25 |
Vatalanib Dihydrochloride
|
25 mg |
|
|
BioVision |
2026-5 |
Vatalanib, Free Base
|
5 mg |
|
|
BioVision |
2025-5 |
Vatalanib Dihydrochloride
|
5 mg |
|
|
BioVision |
2024-5 |
Tandutinib
|
5 mg |
|
|
BioVision |
2024-25 |
Tandutinib
|
25 mg |
|
|
BioVision |
2023-5 |
Neratinib
|
5 mg |
|
|
BioVision |
2023-25 |
Neratinib
|
25 mg |
|
|
BioVision |
2021-25 |
NSC-687852
|
25 mg |
|
|
BioVision |
2022-5 |
Motesanib
|
5 mg |
|
|
BioVision |
2022-25 |
Motesanib
|
25 mg |
|
|
BioVision |
2019-25 |
SQ 22536
|
25 mg |
|
|
BioVision |
2020-10 |
(±)-Thalidomide
|
10 mg |
|
|
BioVision |
2020-50 |
(±)-Thalidomide
|
50 mg |
|
|
BioVision |
2021-5 |
NSC-687852
|
5 mg |
|
|
BioVision |
2018-5 |
ZM 447439
|
5 mg |
|
|
BioVision |
2019-5 |
SQ 22536
|
5 mg |
|
|
BioVision |
2016-25 |
LDN-57444
|
25 mg |
|
|